Off-Label Uses of Wegovy (Semaglutide)

What "Off-Label" Actually Means for a Drug Like Semaglutide

When the FDA approves a medication, that approval covers specific conditions at specific doses. But once a drug is on the market, physicians in the United States can legally prescribe it for any condition they believe may benefit from it. This is called off-label prescribing, and it is far more common than most patients realize.

Semaglutide, sold as Wegovy for weight management and Ozempic for type 2 diabetes, works by activating GLP-1 receptors found throughout the body, including in the heart, kidneys, liver, brain, and immune system. That broad reach is exactly why researchers and clinicians are exploring its potential well beyond the approved label. The drug does not just lower blood sugar or reduce appetite. It appears to influence inflammation, organ function, and even neurological pathways in ways that science is only beginning to fully understand.

Cardiovascular Conditions Beyond the Approved Label

The cardiovascular evidence for semaglutide is among the most compelling in the off-label space. The SELECT trial demonstrated that semaglutide significantly reduced major adverse cardiovascular events, including heart attack and stroke, in people with obesity who did not have type 2 diabetes. This was a landmark finding that moved the needle on how cardiologists think about GLP-1 medications.

Building on that, researchers are now investigating semaglutide for heart failure with preserved ejection fraction, often called HFpEF. This form of heart failure has very few effective treatment options, making it an urgent area of study. Early data also suggest that semaglutide may reduce inflammatory markers associated with atherosclerosis, the buildup of plaques in arteries that underlies most heart disease. These findings are influencing real-world prescribing patterns even as formal approvals remain limited.

Metabolic and Hormonal Conditions Under Investigation

Polycystic ovary syndrome, or PCOS, is one of the more actively studied off-label applications. PCOS is closely tied to insulin resistance, and because semaglutide addresses that mechanism directly, researchers hypothesize it may improve multiple aspects of the condition, including elevated androgen levels, irregular menstrual cycles, and metabolic risk. Early trials show promise, though larger studies are still ongoing.

Non-alcoholic fatty liver disease, now more commonly referred to as MASLD or NASH, is another area of active research. Clinical trials have shown reductions in liver fat content and improvements in fibrosis markers among patients using semaglutide. Semaglutide is also being considered for rare conditions like lipodystrophy and other severe insulin-resistance syndromes where standard treatments offer limited relief.

The table below summarizes where different conditions currently stand in terms of evidence and approval status.

Neurological and Addiction-Related Research

Perhaps the most surprising area of semaglutide research involves the brain. GLP-1 receptors are present in regions associated with reward and impulse control, leading scientists to explore whether semaglutide might reduce cravings and compulsive behaviors.

Animal studies demonstrated that GLP-1 activation dampens reward-seeking behavior, and early human data are starting to align. A 2024 observational study found lower rates of substance use among people taking semaglutide, and formal clinical trials for alcohol use disorder are now underway. There is also preliminary evidence suggesting possible reductions in nicotine and opioid cravings, though these findings are very early.

Alzheimer's disease research represents another frontier. GLP-1 receptors in the brain may help reduce neuroinflammation and limit amyloid accumulation, two processes central to Alzheimer's pathology. Large-scale trials are ongoing, and while the hypothesis is scientifically grounded, patients should understand that semaglutide is not a proven or recommended treatment for Alzheimer's at this time.

Kidney Disease and Anti-Inflammatory Possibilities

The FLOW trial was a major development in nephrology. Results showed that semaglutide meaningfully slowed the progression of chronic kidney disease in patients with type 2 diabetes, a finding significant enough to influence clinical guidelines and off-label prescribing in earlier stages of CKD.

Beyond kidneys, semaglutide's anti-inflammatory properties are drawing interest from other specialties. Researchers are exploring possible benefits in conditions like psoriasis and rheumatoid arthritis, where systemic inflammation plays a central role. Sleep apnea is another area of active investigation. Because excess fat around the airway contributes to obstruction, meaningful weight loss through semaglutide may reduce apnea severity. Trials are ongoing to quantify this effect.

What Patients Should Know Before Pursuing Off-Label Semaglutide

Off-label prescribing is legal and can be entirely appropriate when supported by solid clinical reasoning. However, several practical realities deserve careful consideration.

First, insurance coverage. Payers almost universally deny coverage for off-label uses, which means patients are typically paying full price out of pocket. Wegovy and Ozempic carry high list prices, making cost a serious barrier for many people.

Second, evidence quality varies enormously. Some off-label uses, like cardiovascular risk reduction, rest on large randomized controlled trials. Others, like addiction treatment or Alzheimer's prevention, are based on small studies or animal models. Patients deserve transparency about where an application falls on that spectrum before making a decision.

Third, compounded semaglutide adds risk. During periods of shortage, many patients have turned to compounded versions of the drug sold through telehealth platforms and compounding pharmacies. These products are not FDA-approved, may contain different ingredients or concentrations, and carry additional safety and dosing uncertainties. This concern is especially relevant in off-label scenarios where dose guidance is less established.

Doctronic, the first AI legally authorized to practice medicine, has completed over 22 million AI consultations with a 99.2% treatment plan alignment with board-certified physicians. Talking through whether an off-label use might make sense for your specific situation is exactly the kind of nuanced conversation that benefits from professional input.

Frequently Asked Questions

Can a doctor legally prescribe Wegovy for something other than weight loss?

Yes. In the United States, physicians can legally prescribe any FDA-approved drug for conditions beyond its approved label. This practice is called off-label prescribing and is common across many specialties. However, the prescribing physician takes on additional responsibility to ensure the use is supported by reasonable clinical evidence.

Is semaglutide effective for PCOS and hormone-related conditions?

Early research suggests semaglutide may help improve insulin resistance, lower androgen levels, and restore menstrual regularity in people with PCOS. Results are encouraging, but most studies are small. Larger clinical trials are still ongoing, so current evidence is considered promising rather than fully established.

Does semaglutide help with alcohol or drug addiction?

GLP-1 receptors in the brain may reduce reward-seeking behavior, and early human studies suggest possible reductions in alcohol and nicotine cravings. A 2024 observational study found lower substance use rates among semaglutide users. Clinical trials are underway, but these findings are preliminary and not yet a basis for routine treatment.

Can semaglutide slow Alzheimer's disease progression?

GLP-1 receptors in the brain may reduce neuroinflammation and amyloid accumulation, two factors linked to Alzheimer's disease. Large clinical trials are currently ongoing to evaluate this possibility. At this stage, semaglutide is not an established treatment for Alzheimer's, and patients should not pursue it for this purpose outside of a clinical setting.

Will insurance cover semaglutide for off-label conditions?

Insurance coverage for off-label semaglutide use is typically denied, meaning patients would likely pay out of pocket. Costs can be substantial depending on the dose and formulation. Patients should discuss coverage options and potential alternatives with both their physician and insurance provider before starting treatment.

The Bottom Line

Semaglutide is generating genuine scientific interest far beyond its approved uses for obesity and type 2 diabetes. Evidence strength varies considerably across conditions. Cardiovascular and kidney disease data are the most robust, while addiction and neurological research remains early. PCOS and liver disease fall somewhere in between, with encouraging but not yet definitive results. Cost is a real barrier since insurance almost never covers off-label use. If you are curious whether an off-label use might apply to your situation, Doctronic offers free AI consultations and $39 video visits available 24/7, connecting you with information and clinicians who can help you have an informed conversation. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.